An assessment of the prescribing preferences of Irish dermatology consultants for the treatment of severe psoriasis in the setting of a cancer diagnosis.

AIM: We aimed to investigate the systemic and biologic agent choices of dermatologists in Ireland for those patients with psoriasis and a cancer diagnosis.

METHODS

An electronic questionnaire was circulated to the Irish Association of Dermatology members using the survey platform, Jotform, between December 2023-June 2025.

RESULTS

In total there were 27 responses. Methotrexate was selected most commonly for all scenarios > 5 years remission. In all clinical scenarios, fumaric acid esters were the least frequently selected agents. In general, tumour necrosis factor-alpha inhibitors were the next least commonly selected. Apremilast was selected most commonly for a current malignancy of stage 1 breast cancer (26%), lymphoma (22%) and metastatic RCC (30%).

CONCLUSION

In general, systemic and biologic agents are used by Irish dermatologists in the setting of psoriasis and cancer.